Bio-Works Technologies (BIOWKS) Q2 2026 earnings summary

Executive summary

• Net sales rose 53% year-over-year to 20.0 MSEK in Q2 2026, with operating profit improving to -3.1 MSEK from -7.6 MSEK.

• For the first half of 2026, net sales increased 123% to 49.3 MSEK, and operating profit reached 1.1 MSEK compared to -15.4 MSEK a year earlier.

• Order intake declined to 8.9 MSEK in Q2 and 24.4 MSEK year-to-date, reflecting variability due to reliance on a few large customers.

• Cash and cash equivalents stood at 30.0 MSEK at the end of June 2026.

• Leadership transition announced, with Eva Lindskog appointed CEO effective November 1, 2026.

Financial highlights

• Q2 net sales: 20.0 (13.1) MSEK, up 53% year-over-year.

• Q2 operating profit: -3.1 (-7.6) MSEK; Q2 net profit: -2.5 (-7.3) MSEK.

• H1 net sales: 49.3 (22.1) MSEK, up 123%; H1 operating profit: 1.1 (-15.4) MSEK; H1 net profit: 2.2 (-15.3) MSEK.

• Cash flow from operating activities: -10.9 (-3.1) MSEK in Q2; -5.6 (-7.6) MSEK in H1.

• Equity ratio improved to 86% from 59% year-over-year.

Outlook and guidance

• Focus remains on strengthening commercial efforts and achieving more predictable, sustainable sales growth.

• No formal forecasts provided.